key: cord-0708928-jy5gsltb authors: Briscoe, Michael; Sykes, Robert; Krystofiak, Thomas; Peck, Oliver; Mangion, Kenneth; Berry, Colin title: Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury date: 2021-01-27 journal: Clin Cardiol DOI: 10.1002/clc.23530 sha: 45a0503adc77045f00894cdc46134cc49db83616 doc_id: 708928 cord_uid: jy5gsltb BACKGROUND: The clinical significance of Coronavirus disease 2019 (COVID‐19) as an associate of myocardial injury is controversial. HYPOTHESIS: Type 2 MI/Myocardial Injury are associated with worse outcomes if complicated by COVID‐19. METHODS: This longitudinal cohort study involved consecutive patients admitted to a large urban hospital. Myocardial injury was determined using laboratory records as ≥1 hs‐TnI result >99th percentile (male: >34 ng/L; female: >16 ng/L). Endotypes were defined according to the Fourth Universal Definition of Myocardial Infarction (MI) and COVID‐19 determined using PCR. Outcomes of patients with myocardial injury with and without COVID‐19 were assessed. RESULTS: Of 346 hospitalized patients with elevated hs‐TnI, 35 (10.1%) had laboratory‐confirmed COVID‐19 (median age [IQR]; 65 [59–74]; 64.8% male vs. COVID‐19 negative: 74 [63–83] years; 43.7% male). Cardiac endotypes by COVID‐19 status (yes vs. no) were: Type 1 MI (0 [0%] vs. 115 [100%]; p < .0005), Type 2 MI (13 [16.5%] vs. 66 [83.5%]; p = .045), and non‐ischemic myocardial injury (cardiac: 4 [5.8%] vs. 65 [94.2%]; p = .191, non‐cardiac:19 [22.9%] vs. 64 [77.%]; p < .0005). COVID‐19 patients had less comorbidity (median [IQR] Charlson Comorbidity Index: 3.0 [3.0] vs. 5.0 [4.0]; p = .001), similar hs‐TnI concentrations (median [IQR] initial: 46 [113] vs. 62 [138]; p = .199, peak: 122 [474] vs. 79 [220] ng/L; p = .564), longer admission (days) (median [IQR]: 14[19] vs. 6[12]; p = .001) and higher in‐hospital mortality (63.9% vs. 11.3%; OR = 13.2; 95%CI: 5.90, 29.7). CONCLUSIONS: Cardiac sequelae of COVID‐19 typically manifest as Non‐cardiac myocardial injury/Type 2MI in younger patients with less co‐morbidity. Paradoxically, the admission duration and in‐hospital mortality are increased. Conclusions: Cardiac sequelae of COVID-19 typically manifest as Non-cardiac myocardial injury/Type 2MI in younger patients with less co-morbidity. Paradoxically, the admission duration and in-hospital mortality are increased. coronavirus, COVID-19, myocardial Injury, outcomes, troponin, Type 2 myocardial infarction Coronavirus disease 2019 (COVID-19) is a novel cause of myocardial injury. 1 The importance of elevated cardiac troponin I (cTnI) in patients requiring intensive care has been extensively documented. 2, 3 What is less well understood is the clinical significance of troponin elevation in COVID-19 including in comparison with other causes of myocardial injury. of patients with COVID-19. Myocardial injury may be due to primary viral infection, secondary hypoxia, inflammatory state, hypotension, thromboembolism, or a combination of these problems. 4 Mechanistic studies of the cardiac and multisystem effects of infection are on-going (ClinicalTrials.gov identifier NCT04403607). 5 Non-ischemic myocardial injury (cardiac or non-cardiac) and Type 2 myocardial infarction (T2MI) generally portend an adverse prognosis, however, evidence-based treatment options are less well established than is the case for Type 1 MI. Troponin-I elevation is associated with fatal outcomes, however the etiology of this elevation is unclear.. 6 We prospectively investigated a population of consecutively admitted patients with myocardial injury in relation to COVID-19 status. We hypothesized that in patients with myocardial injury, COVID-19 would associate with Type 2 MI more so than with other endotypes, and this combination would be an adverse prognostic factor for in-hospital outcomes. A diagnosis of COVID-19 was determined by either laboratory evidence of SARS-CoV-2 infection by PCR biospecimen testing and/or a radiological diagnosis (chest computed tomography, chest radiograph) consistent with COVID-19 but biospecimen negative with a clinical presentation in keeping with SARS-CoV-2 infection. The laboratory tests used were either the Roche Cobas 6800 or Seegene SARS-CoV-2 tests. The characteristics of patients with COVID-19 infection and Type 2 MI or myocardial injury compared with those without COVID-19 infection are described in Table 1 The ECG features are described in Table S3 , including patients with a diagnosis of Type 1 MI from the initial cohort. Patients with Type 2 MI or myocardial injury, less frequently underwent further coronary assessment with either CT coronary angiography (n = 5) or invasive catheter angiography (n = 6). Cardiac MRI was performed in patients with a diagnosis of myocarditis in addition to clinical and ECG assessment. Physiological stress-induced cardiac myocardial injury (i.e., hemodynamic shock, invasive ventilation, inotropic therapy) was the most prevalent cause for patients with COVID-19 infection (27.8% vs. 3.5%, p < .001). Myocarditis/pericarditis was listed as causative in 8.3% COVID-19 positive patients compared to 2.9% of all COVID-19 negative patients (p = .116). Hypotension (8.3%) and hypertension (2.8%) were also implicated as causal associations for myocardial injury in the COVID-19 positive patients, however these were not significant between groups ( Figure 2 and Table S1 ). Cardiac causes of myocardial injury (Table S1) were more common in patients without COVID-19 (positive: 11.1% vs. negative: 33.3%, p = .022), of which tachyarrhythmia and heart failure were the most likely mechanisms (15.7% and 15.1% respectively). Within this cohort, hypoxia was the most likely (Figure 3 and Table S2 ). Vital status was determined in all patients by assessment of electronic patient records. The duration of follow-up was a median of 71 days (inter- We have provided novel information on the nature and clinical significance of COVID-19 in a hospitalized population with myocardial injury. Our study involved prospective clinical evaluation of consecutive patients in real-time during the study period. Cases of myocardial injury were identified based on a high sensitivity troponin result >URL. This approach was intended to minimize missing data and selection bias. We found that the cardiac sequelae of COVID-19 Type 2 MI/myocardial injury is associated with increased illness severity as evidenced by significantly higher mortality and duration of hospital stay. 16 Though exact mechanisms of myocardial injury and modifiable outcome in patients with COVID-19 is yet to be demonstrated, protocolized high-sensitivity troponin testing and its utilization in stratification could be a useful tool for early recognition of adverse outcome and early decision making in this group. 17 The occurrence of myocardial injury and COVID-19 is associated with a high in-hospital mortality. Type 2 MI or myocardial injury in COVID-19 infection has poorer in-hospital outcomes compared with other causes of Type 2 MI or myocardial injury. Myocardial injury in severe COVID-19 infection Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 and cardiovascular disease The Chief Scientist Office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study Cardiac troponin-I and COVID-19: a prognostic tool for in-hospital mortality Causes of Death and Comorbidities in Patients with COVID-19 Cardiac arrhythmias in COVID-19 infection Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneunmonia in Wuhan, China Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection OpenSAFELY: factors associated with COVID-19 related hospital death in the linked electronic health records of 17 million adult NHS patients, medRxiv High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections Obesity is associated with left atrial enlargement, E/A reversal and left ventricular hypertrophy Obesity as a predictor for poor prognosis of COVID-19: a systematic review Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis Myocardial injury and COVID-19: serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease (RE/18/6134217). The authors declare no potential conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.